Consistent with this, their previous studies revealed that OPN-b and OPN-c probably combat anti-angiogenesis effects of curcumin (CUR), with conventional AML regimen, via induction of the AKT/VEGF/STAT3/CXCR4/IL-6 molecular pathway [91]. Here, AKT1 is linked to acute myeloid leukemia.